EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 266 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer Research UK spin-out goes public, ready to invest more in... May 17, 2021 Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 Male Patients with Cancer at Higher Risk of Severe Disease Course... August 26, 2020 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Load more HOT NEWS Health inequalities: Why do people smoke if they know it’s bad... El cáncer en mi comunidad: Superar los retrasos en la atención... Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer
